Taysha Gene Therapies (TSHA) Misses Q3 EPS by 27c
Tweet
Share
E-mailGet Alerts TSHA Hot Sheet
Join SI Premium – FREE
Taysha Gene Therapies (NASDAQ: TSHA) reported Q3 EPS of ($1.35), $0.27 worse than the analyst estimate of ($1.08).
For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- Abivax reports Phase 3 maintenance trial results for obefazimod
- Methanex to idle Trinidad Titan plant after gas contract talks fail
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
